Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This is a multicenter, double-blind, placebo-controlled, parallel-design study. The study will enroll approximately 210 adult male and female subjects with stage 3 or 4 chronic kidney disease and metabolic acidosis. The study dosing (TRC101 or placebo) will continue for 12 weeks once daily. The maximum study duration is anticipated to be up to 16 weeks.
Epistemonikos ID: 889f0639384bdbbc4ff9371058064069462bb92e
First added on: May 21, 2024